Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Harpoon Therapeutics, Inc. Common Stock (HARP)

Biological Products, (no Disgnostic Substances)

https://www.harpoontx.com

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

611 GATEWAY BOULEVARD, SUITE 400
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/08/2019

Market Cap

865,079,358

Shares Outstanding

16,950,000

Weighted SO

16,948,331

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

PASG --.--%

BDTX --.--%

TCRR --.--%

ALEC --.--%

STOK --.--%

FIXX --.--%

ADAP --.--%

RVMD --.--%

Beta

1.5478

Last Div

0.0000

Range

3.11-23.21

Chg

0.0200

Avg Vol

1129503

Mkt Cap

865079358

Exch

NASDAQ

Country

US

Phone

650 443 7400

DCF Diff

1.7850

DCF

2.7850

Div Yield

0.0000

P/S

23.1670

EV Multiple

-23.5027

P/FV

20.0051

Div Yield %

0.0000

P/E

-2.9432

PEG

-0.0613

Payout

0.0000

Current Ratio

1.8942

Quick Ratio

1.7457

Cash Ratio

0.9797

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

444.7588

CCC

-444.7588

Gross Margin

0.9245

Op Margin

-1.0477

Pretax Margin

-0.8168

Net Margin

-0.8266

Eff Tax Rate

-0.0394

ROA

-0.6487

ROE

-9.0427

ROCE

-1.3275

NI/EBT

1.0120

EBT/EBIT

0.7796

EBIT/Rev

-1.0477

Debt Ratio

0.3048

D/E

3.1940

LT Debt/Cap

0.7174

Total Debt/Cap

0.7616

Int Coverage

56.4545

CF/Debt

-4.7836

Equity Multi

10.4774

Rec Turnover

0.0000

Pay Turnover

0.8207

Inv Turnover

0.0000

FA Turnover

3.0153

Asset Turnover

0.7848

OCF/Share

-17.5737

FCF/Share

-17.6039

Cash/Share

8.0061

OCF/Sales

-1.8580

FCF/OCF

1.0017

CF Coverage

-4.7836

ST Coverage

-23.3292

CapEx Coverage

-583.0336

Div&CapEx Cov

-583.0336

P/BV

20.0051

P/B

20.0051

P/S

23.1670

P/E

-2.9432

P/FCF

-12.4472

P/OCF

-1.3093

P/CF

-1.3093

PEG

-0.0613

P/S

23.1670

EV Multiple

-23.5027

P/FV

20.0051

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jan 23, 08:45 This 1 Bullish Move by Merck Could Drive Growth for Years to Come MarketWatch Jan 08, 16:42 Dow ends higher after third session of gains, as bond yields pull back MarketWatch Jan 08, 16:42 Dow ends higher after third session of gains, as bond yields pull back MarketWatch Jan 08, 14:49 Dow rises as yields fall, while tech buoys S&P 500, Nasdaq MarketWatch Jan 08, 14:49 Dow rises as yields fall, while tech buoys S&P 500, Nasdaq MarketWatch Jan 08, 13:44 Dow edges lower as Boeing falls, while tech buoys S&P 500, Nasdaq MarketWatch Jan 08, 11:53 Dow dragged down by Boeing shares as tech buoys S&P 500, Nasdaq MarketWatch Jan 08, 08:43 Dow futures down 100 points, pressured by Boeing, Fed trajectory MarketWatch Jan 08, 07:53 Merck to pay 118% premium to buy cancer drugmaker Harpoon Therapeutics MarketWatch Jan 08, 06:49 Wall Street’s most celebrated bear is not a bull yet. Here’s Mike Wilson’s stock-market playbook for three economic scenarios. GlobeNewswire Inc. Dec 26, 07:30 Harpoon Therapeutics Strengthens Leadership Team GlobeNewswire Inc. Dec 11, 20:15 Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D) GlobeNewswire Inc. Dec 11, 20:15 Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D) GlobeNewswire Inc. Dec 11, 20:15 Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D) GlobeNewswire Inc. Nov 02, 09:15 Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Revenue Product Segmentation